Amarin Q3 2023: Revenue $66M (-27% YoY), net loss $19.3M; cash flow +$8M

AMARIN CORP PLCUK

2023-Q3 EPS reported -$0.13 revenue$232,198,000

Total net revenue $66.1M, down 27% vs Q3 2022; net loss $19.3M vs $5.1M loss a year ago; diluted EPS loss $0.05.
U.S. net product revenue $62.4M (-3% sequentially); maintained ~57% IPE market share despite generic competition.
European revenue $0.8M; early launches in UK, Spain, Netherlands with progress under new leadership.
Generated $8M positive cash flow in quarter; cash and investments $321M; on track for $40M annual savings from July restructuring.
Partner Edding launched VASCEPA in China for severe hypertriglyceridemia; submitted CVRR indication filing to NMPA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AMARIN CORP PLCUK reported three and nine months ended September 30, 2023 results: revenue Total net revenue for the three months ended September 30, 2023, was $66.1 million.

Period: three and nine months ended September 30, 2023
Revenue: Total net revenue for the three months ended September 30, 2023, was $66.1 million
Result: reported results

Exact text from the filing

Total net revenue for the three months ended September 30, 2023, was $66.1 million, compared to $89.9 million in the corresponding period of 2022, a decrease of 27%.

View on SEC.gov

Browse all earnings releases →

AMARIN CORP PLCUK filing history →

Source: SEC EDGAR

accession 0000950170-23-057121

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.